The short version
In September 2023, Globus Medical closed its acquisition of NuVasive. I manage contracting for a regional hospital that does a high volume of spine surgery, so this merger touched my purchase orders directly. We used NuVasive's MIS systems before the deal and kept using NuVasive and Globus Medical products afterwards, but now under one vendor umbrella. The merger is often described in terms of products and market share. For a hospital buyer, the change was more practical: one less vendor to enroll, one less portal to log into, one less compliance review every year.
There is an operational benefit, but the bigger thing the merger did was expose how poorly most hospital supply teams measure actual costs. If you take one idea from the Globus Medical NuVasive merger, make it this: total cost of ownership beats unit price every single time. Unit price gets the attention. Total cost determines whether you get budget approval next year.
This framework applies far beyond spine implants. I use it when selecting an infection control product, restocking ostomy supplies for our wound clinic, and evaluating a shockwave therapy system for our rehab service.
Globus Medical NuVasive merger: what it looked like inside a hospital
Globus Medical announced its intent to acquire NuVasive in April 2023, and the transaction closed in September 2023. Globus contributed spine implants, robotic navigation and enabling technology; NuVasive contributed the XLIF lateral procedure and other MIS approaches, plus intraoperative neuromonitoring. Investors focused on scale, surgeon preferences, and sales coverage. My focus was simpler: What happens to my existing contracts, inventory, and service response times?
In the first months after close, the answer was administrative. We needed a consolidated master contract. We had NuVasive purchase history in one system and Globus purchase history in another. Our accounts payable team had to reconcile two invoice styles due to migration. I remember a vendor credentialing form—I want to say we had to redo it three times before the new legal entity showed up in the system. Honestly, that's the part leadership never puts in the cost of synergy.
But the integration eventually delivered what it promised. By mid-2024, our monthly PO count for the combined spine portfolio dropped by roughly a third. Not the spend—just the number of orders. Consolidating freight and purchasing schedules was easier with a single account manager, simpler order templates, and one set of product codes. We stopped chasing missing invoices from the legacy NuVasive system.
I have mixed feelings about fewer device vendors overall. Part of me worries about losing negotiating leverage when a hospital has fewer alternatives to pit against each other. Another part of me remembers the cost of maintaining redundant supplier files. I've landed on a compromise: fewer vendors, but with more specific service-level commitments written into the contract and a yearly benchmark clause.
The real lesson: after a merger, rethink how you define cheap
When I started in hospital procurement in 2020, I compared quotes by staring at the unit price column. It took a near-miss with an infection control product to break that habit.
In 2024, an infection control product supplier offered us wipes at about 18 percent below the incumbent. The sample killed the same organisms, and the EPA registration looked fine. This was during our vendor consolidation drive, so the pressure to say yes existed. Then our infection prevention nurse asked a simple question: What is the contact time?
The discount product needed twice as long as our current wipes to reach its label claim. Our operating rooms turn over quickly, and room turnover includes time for surfaces to stay visibly wet. In a busy spine service, a few extra minutes per room means delayed cases or overtime. The product was cheaper per dollar and more expensive per day. We passed.
That experience became the template. I now ask four questions before any of my analysts sends a quote to a service line:
- What is the acquisition price per unit, including freight and any unseen fees?
- What does it cost in staff time to receive, store, train on, and use it?
- What compliance and clinical factors complicate it, from dwell time to compatibility?
- What is the cost when it fails, for example a disinfectant that needs a second pass or an implant that is not the right fit?
The total-cost answer is often different from the price answer. It is also the answer that survives contact with an OR schedule.
Infection control product example
Infection control products don't exist in a vacuum. The CDC's Guideline for Disinfection and Sterilization in Healthcare Facilities (last updated 2019) shapes what we ask for, but the practical choice belongs to each facility. I have learned to require the label's stated contact time in every product evaluation. If a disinfectant needs ten minutes and your room turnover target is twenty minutes, you're using half the available time on disinfection. A faster product may cost more per gallon and less per room. That math is not always intuitive.
Ostomy supplies: where the price of a leak is hidden
Ostomy supplies feel like a commodity category: pouches, skin barriers, flanges, adhesive removers. Budget reviews tend to compare pouch prices across suppliers. But the buyer who only compares pouch prices is missing the entire point of the category. An ostomy appliance fails when effluent reaches skin. Skin breakdown leads to clinic visits, home care nursing, extra dressings and sometimes hospital admission.
Our wound and ostomy clinic now evaluates skin barriers and flanges based on wear time and leakage reports, not just unit cost. A barrier that costs more and wears an extra day can easily reduce overall spend. I cannot verify adhesion claims myself, so I ask suppliers for their published clinical evidence and for a sample trial with our ostomy nurses. The product with the cheapest price is rarely the product with the lowest total cost.
What is shockwave therapy? Asking before buying
When our rehab clinic requested a shockwave therapy machine, finance asked the question you're probably asking: what is shockwave therapy? In plain terms, extracorporeal shockwave therapy (ESWT) uses acoustic pulses delivered to injured tissue. Common uses include plantar fasciitis, Achilles tendinopathy, tennis elbow and certain shoulder calcifications. It is an office-based, nonsurgical option, which appeals to patients and payers, if coverage exists.
For procurement, ESWT is a capital purchase that follows the same total-cost logic. The machine price on the quote is one small part. You need to confirm service contracts, staff training, treatment consumables, software updates, and whether the device is FDA-cleared for the indications your clinicians will treat. More importantly: is the expected patient volume enough to cover the cost of the program? I've seen clinics buy a second machine because the first one lacked output settings and was taking too long per patient. The cheap device became the expensive experiment.
No clinician should recommend shockwave therapy when there is a clear surgical indication, and no buyer should compare devices without a written indication list. When used properly, ESWT is another tool. When bought carelessly, it is an underused capital asset.
Boundaries: where this framework is not enough
I don't want to oversell the total-cost approach. It cannot fix a weak negotiating position. If your facility is the only hospital within a hundred miles, a device maker's rep has different leverage than in a city with four competing health systems. TCO makes trade-offs visible, but it does not make them disappear.
There is also a time limit on merger-based conclusions. This was accurate as of January 2025. The NuVasive and Globus Medical integration is still working through product rationalization, coding and contracts. If you are comparing legacy NuVasive items to newer Globus Medical catalog numbers, verify what is currently available before you build a long-term contract. Also, pricing data from an old portal is not a valid baseline.
And yes, part of me still misses the simplicity of picking one vendor for each procedure. The merger made that easier. But the deeper work—measuring cost honestly—is never over.
